Tuesday, January 25, 2022 2:57:36 AM
I heard all his interviews of the last 7 months. We can believe on good clinical results for Reborn and Reduvo. But this is all.
Reduvo might get approval according his message in 1st quarter but January is the most optimistic case.
Reborn results: nobody knows. Hopefully in 2022.
I am long and patient but my investment timing would have been totally different if he would have said in June 21 the truth. He is just another not trustworthy OTC CEO. I should have known better. My mistake not checking the history of his promises before investing.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM